Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
AIMS: To study the implications of European guidelines on the use of antihypertensives and/or lipid-lowering drugs (LLDs) for primary prevention in a Norwegian population. METHODS AND RESULTS: The Tromsø study is a population-based study in the municipality Tromsø, Norway (from 1974 to till now). This analysis includes 45-79-year-old participants in 2001 (n = 6362, attendance rate 86%). From the age of 60 years in men and 70 years in women, almost all participants were defined as high-risk individuals according to the European guidelines, with established cardiovascular disease, diabetes, or a 10-year risk score of > or =5%. In the primary prevention subgroup of the 45-64-year-olds, recommended antihypertensive and/or LLD use would be higher in men only, 42% compared with 12% on current medication. Among the 65-79-year-olds, >90% would be eligible for antihypertensives and/or LLDs in both sexes when compared with current treatment rates of <30%. In total, 40% of all participants aged 45-79 would be candidates for primary prevention, compared with 15% on current medication. CONCLUSION: The implementation of the European guidelines could imply a doubling of the numbers of Norwegian adults on cardiovascular medication for primary prevention. Contributors to the increase would be more frequent drug use in men and elderly people, particularly for LLD use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Results of a Norwegian study suggest that using the European SCORE assessment would double the number of individuals who need drugs for primary prevention of CVD.548”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [548]
Citations
Cites
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
Self-citation(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378 · cited 1×
“Although the beneficial effects of antihypertensives among elderly people are well documented, the documentation of the beneficial effects of LLDs on total and CVD mortality is more limited.(15) More specific guidance to preventive LLD intervention in elderly people is warranted if the European guidelines are to be fu…”
Background(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251 · cited 2×
“0 mmol/L.(1) We calculated a delta (D) percentage, which expresses the difference between recommended and observed current drug use in the Tromsø study (percentage of users according to recommended European guidelines minus percentage of current users).”
BackgroundTunstall-Pedoe, H., Kuulasmaa, K., Mähönen, M., Tolonen, H., & Ruokokoski, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04021-0 · Cited by 1,444
EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE
Backer, G. D., Ambrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., et al. (2005) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2005-1-3-57-65 · Cited by 1,267
Confidence intervals for a binomial proportion
Vollset, S. E. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120902 · Cited by 477
Research works printed but not linked: 3
- Wilsgaard T. Longitudinal analysis of cardiovascular risk factors. Thesis, University of Tromsø, Tromsø, Norway, 2002.
- Furu K, Skurtveit S, Rosvold EO. Drug use question in Norwegian health surveys–response rate and agreement between specific and open-ended questions. Norw J Epidemiol2003;13:147–154.
- Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics. London: Joint publication by the British Heart Foundation, European Heart Network and the Health Economics Research Centre at the University of Oxford; 2005. http://heartstats.org./uploads/documents%5CPDF.pdf (26 June 2005).
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Metadata
- Authors
- Hartz, I., Njølstad, I., & Eggen, A. E.
- Affiliations
- UiT The Arctic University of Norway (NO)
- Corresponding author
- Hartz, Ingeborg
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-04
- Volume
- 26
- Issue
- 24
- Pages
- 2673-2680
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2157715149
- Cited by
- 61
- References
- 15
- Citations by year
- 2022: 2 · 2017: 1 · 2016: 5 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 11
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Universitetet i Tromsø
- Høgskolen i Hedmark
- Norwegian Institute of Public Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- SCORE risk model, primary prevention, cardiovascular drug use, antihypertensive drugs, lipid-lowering drugs, guideline implementation, cardiovascular risk, sex differences, older adults, Tromsø Study
- MeSH terms
- Aged, Antihypertensive Agents, Hypolipidemic Agents, Blood Pressure, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Norway, Risk Factors, Incidence, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. https://app.cochat.ai/papers/10.1093/eurheartj/ehi556
- The paper
- Hartz, I., Njølstad, I., & Eggen, A. E. (2005). Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.